ACER Insider Trading

Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 20.20%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Acer Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Acer Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$1M-$500k$0$500k$1MTotal Insider BuyingTotal Insider Selling

Acer Therapeutics Share Price & Price History

Current Price: $0.66
Price Change: Price Decrease of -0.1444 (-17.95%)
As of 11/21/2023 12:59 AM ET

This chart shows the closing price history over time for ACER up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Acer Therapeutics Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for Acer Therapeutics (NASDAQ:ACER)

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ACER by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
202220232024$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4-$400k-$200k$0$200k$400kTotal InflowsTotal Outflows
Acer Therapeutics logo
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company's pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder. The company was incorporated in 1991 and is headquartered in Newton, Massachusetts.
Read More on Acer Therapeutics

Today's Range

Now: $0.66
Low: $0.66
High: $0.85

50 Day Range

MA: $0.74
Low: $0.66
High: $0.90

52 Week Range

Now: $0.66
Low: $0.55
High: $4.56

Volume

574,600 shs

Average Volume

N/A

Market Capitalization

$16.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A